EGFR and lung cancer: Interestingly, the combination is undergoing clinical evaluation in a phase II trial (ClinicalTrials.gov NCT04545710), started in September 2020, that has been evaluating abemaciclib combined with osimertinib in resistant EGFR mutated lung cancer patients post progression on osimertinib.